The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...
5don MSN
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...
3d
News Medical on MSNRadiation and immunotherapy help preserve bladders in patients with muscle-invasive bladder cancerPatients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
For comparison, Imfinzi given on its own every four weeks achieved an OS of 13.6 months, while for a regimen of tremelimumab alone it was 15.1 months and 11.3 months for another regimen based on ...
AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...
AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...
2d
Zacks.com on MSNAstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results